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Summary Monoclonal antibody SP-2 to the tumour-associated antigen 90K was generated by immunisation
with conditioned medium of human breast cancer cells. We investigated whether circulating levels of 90K can
influence the prognosis of patients with breast cancer. Serum samples were obtained from 425 patients with
histologically proven breast cancer with no clinical evidence ofdisease after surgery (NED) and in 310 patients
with metastatic disease. Serum 90K was determined by a new immunoradiometric assay (IRMA). Antigen
levels in NED patients were elevated in 18.5% of cases, mean levels being higher than in healthy controls
(P = 0.001). Among 375 evaluable patients, the 75-month overall survival for 90K-negative (< 11 U ml-') and
90K-positive (>11 U ml- ) patients was 78% and 53% respectively (P = 0.004). The prognostic value of 90K
appeared to be limited to patients with node-positive disease. Number of metastatic axillary lymph nodes and
level of 90K antigen were the only independent variables for predicting overall survival. Patients with
metastatic breast cancer had elevated 90K in 51.3% of cases. High 90K levels were significantly associated
with the presence of metastases to liver, shorter disease-free interval and younger age. We conclude that an
elevated 90K antigen level in serum is a predictor of poor prognosis in breast cancer.
Human neoplasms may express and release into the circula-
tion a variety of substances collectively referred to as tumour
markers. Serological analysis of these markers in cancer
patients has been used extensively for diagnostic as well as
predictive tests for cancer and metastases. To obtain mono-
clonal antibodies (MAbs) against circulating breast cancer
markers, we immunised mice with proteins released into tis-
sue culture fluid of human breast cancer cells (lacobelli et al.,
1986). One of the MAbs generated, SP-2, identified an
antigen with a molecular weight of approximately 90,000
daltons which is expressed in more than 80% of breast
cancer tissues, but not in non-cancerous normal mammary
gland surrounding the cancer cells (lacobelli et al., 1986). The
MAb SP-2-reactive antigen, designated 90K, is present in
human serum and is elevated in women with breast cancer
(lacobelli et al., 1986). An enzyme-linked immunosorbent
assay (ELISA) has been established with MAb SP-2 to detect
circulating 90K antigen (lacobelli et al., 1988). Using this
method, we demonstrated that 90K serum level is elevated in
approximately 50% of patients with metastatic breast cancer
and correlates with the clinical stage of the disease (Iacobelli
et al., 1988). Since 90K serum levels are not related to other
breast cancer markers such as CA 15-3 or carcinoembryonic
antigen (lacobelli et al., 1988), measurement of 90K could
represent an additional tool for the surveillance of breast
cancer. However, the utility of 90K in terms of monitoring
the clinical course of patients with breast cancer has not yet
been evaluated. Here, we report data showing the prognostic
impact of 90K serum levels in a large cohort of women with
breast cancer. A new immunoradiometric assay (IRMA) to
determine 90K in serum is also described.
Patients and methods
Patients
Between March 1985 and February 1992, sera were collected
from a total of 735 female breast cancer patients (mean age
59 ± 12 years) followed at the Department of Gynecology
and Obstetrics of the University of Turin Medical School.
Among them, 425 patients at entry had no evidence of
disease after surgery (NED) and the remaining 310 patients
were affected by metastatic breast cancer. Serum samples in
NED patients were collected at the time of the first visit, i.e.
1-3 months after breast surgery. Serum samples from
patients with metastatic disease were collected at the time of
the first clinical evaluation or administration of therapy.
Patients were followed up at regular intervals for disease
status, tumour recurrence or death with clinical, radiological
and laboratory examinations. Serum samples from 285
apparently.healthy female blood donors (mean age 46 ± 14
years) were used as normal controls. All serum samples were
stored at -20'C. 90K levels are stable over time in such
samples. Samples were coded and assayed without knowledge
of clinical information.
90K assay
A 'two-step' sandwich IRMA was developed to measure 90K
activity. Polystyrene beads (6.5 mm, Precision Plastic Balls,
Chicago, IL, USA) were coated with biotinylated MAb SP-2
by the protein-avidin-biotin capture (PABC) system (Suter
et al., 1989). Biotinylation of SP-2 was carried out according
to Guesdon et al. (1979). After coating, the beads were
washed extensively with 0.9% sodium chloride solution and
incubated with biotinylated SP-2 (5fig ml-') at room
temperature for 18 h. Coated beads were treated with an
overcoating solution of bovine serum albumin (BSA)
(2 mgml-') for 1 h at room temperature, washed with dis-
tilled water and stored at room temperature until used. Beads
treated in this fashion were stable for at least 6 months.
With each assay, 200-jil aliquots of appropriately diluted
samples or standards were incubated with SP-2-coated beads
for 1 h at 37°C. The beads were washed with distilled water
followed by the addition of 100ll of '25I-labelled SP-2 (ap-
proximately 50,000c.p.m.; specific activity 10 CifLg-1) in
PBS, pH7.4, containing 5% BSA, 0.1mgml-' normal
mouse IgG and 0.1% sodium azide for an additional hour at
37'C. Beads were washed with distilled water and counted in
a gamma-counter. The amount of 90K was calculated by
reference to the amount present in standard preparations
made from a pool of sera from breast cancer patients and
titred to contain 40, 20, 10 and 5 arbitrary units per ml. The
simultaneous assay of 120 sera from breast cancer patients
using the IRMA and the previously developed ELISA
(lacobelli et al., 1988) gave a correlation coefficient of 0.91
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(Kendall Q-test) (data not shown). Compared with ELISA,
IRMA is approximately three times more sensitive, faster to
perform, requiring less than 3 h, and highly reproducible with
an intra-assay variability of 4% ± 0.3% (mean + s.d.,
n = 100). The hybridoma producing SP-2 is available upon
request from S. Iacobelli or CNCM, Institut Pasteur, Paris,
France, code no. 1-1083.
Oestrogen receptor assay
Oestrogen receptors in the primary tumour were assayed by
dextran-coated charcoal according to the EORTC method
(EORTC Breast Cancer Cooperative Group, 1973). Tumour
specimens were considered oestrogen receptor positive if they
contained at least 5 fmol per mg of protein.
Statistical analysis
A computerised database containing continually updated
complete clinical information on each patient was used for
statistical analysis. Patients were considered 90K positive if
the 90K serum level was higher than the upper limit of the
normal range (11 U ml-'). Differences between groups were
evaluated using the Mann-Whitney and Kruskal-Wallis tests
(Kruskal & Wallis, 1952). Correlations between 90K status
(positive or negative) and other clinicopathological features
were evaluated using the chi-square test. Survival was cal-
culated from the day of first 90K measurement by the Kap-
lan-Meier (1958) method. Differences between curves were
analysed using Mantel's log-rank test (Mantel, 1966). The
regression model of Cox (1972) was used to evaluate the
predictive power of various prognostic factors in a multi-
variate manner. Statistical analyses were performed using the
BMDP statistical package (BMDP Statistical Software, Los
Angeles, CA, USA).
Results
Sera from 285 apparently healthy subjects (female blood
donors) were assayed for 90K levels by IRMA (Table I). The
mean 90K serum level in this group was 5.6 ± 2.7 Uml'.
The cut-off value of 90K was arbitrarily set at the mean plus
2 s.d. (11 U ml-') to define the positive rate. The serum level
of 90K was not affected by sex, blood group and menstrual
cycle (not shown). In addition, no influence of age could be
detected when subjects were separated into age groups of 10
years (not shown). These results are in keeping with data of
previous studies in which serum 90K was measured by
ELISA (lacobelli et al., 1988).
Serum 90K in NED breast cancer patients
We obtained serum samples from 425 patients with breast
cancer apparently free of disease after surgery. These patients
were followed up for a median of 62 months from study
entry (range 2-75). During this period, 50 patients were lost
to follow up. Overall, 90K levels were positive in 79 (18.5%)
patients at the first assay of the marker (Table I). The
number of positive cases and the mean level (11.3 ±
8.3 U ml-') were significantly higher than in controls
(P = 0.001).
Table I Distribution of 90K serum levels in normal subjects and
patients with breast cancer
No. of Mean ±s.d. No. ofpositive
Patient population patients (Uml-') cases (%)
Healthy subjects 285 5.6± 2.7 15 (5.2)
Breast cancer
NED 425 11.3±8.3* 79* (18.5)
Metastatic disease 310 17.8±9.3* 159* (51.3)
Cut-offvalue of serum 90K is 11 U ml-' (mean±2 s.d.). *P = 0.001
vs controls.
The relationship between serum 90K status and clinico-
pathological features of NED breast cancer patients is shown
in Table II. There was no statistically significant association
between serum 90K and either age, menopausal status, axil-
lary lymph node involvement, oestrogen receptor (ER) status
or size and histology of the primary tumour. A trend for
patients with larger tumours to be more frequently 90K
positive was not statistically significant (P = 0.06).
At Kaplan-Meier analysis, of the 375 patients for whom
follow up data were available, 223 of 286 patients with initial
90K-negative sera (serum 90K levels < 11 U ml-') survived
for 75 months, whereas those with 90K-positive (90K levels
> 11 U ml- ) sera had a significantly worse outcome (overall
75-month survival 78% vs 53%, Figure la). When node-
negative and node-positive patient subpopulations were
analysed separately, a correlation between poor prognosis
and high value (>11 U ml-') of 90K was observed only for
the latter (Figure lb and c). No significant correlation was
observed between 90K and disease-free survival in both node
categories (not shown).
The interrelationship of various prognostic factors, includ-
ing 90K serum level, with overall survival in patients with
node-positive disease was evaluated. Multivariate analysis
showed that the only independent factors for survival were
the number of metastatic axillary lymph nodes at diagnosis
(P = 0.001) and the initial 90K value (P = 0.005) (Table
III).
In 36 patients, the 90K serum level was measured serially
every 3-6 months for up to 48 months after primary breast
surgery, focusing on its relationship with the occurrence of
distant metastases (Figure 2). Nine patients (25%) were
found to develop metastatic disease within 40 months after
surgery, while the remaining 26 patients did not develop
metastases until up to 48 months. In the group developing
metastases, serum 90K was high (11.9 ± 6.7 U ml') before
breast surgery and decreased thereafter. However, in eight of
nine patients, the 90K level increased again at the time of
metastases, reaching higher levels than before surgery. In
three patients (as shown by an arrow in Figure 2), re-
elevation of the 90K level occurred before the clinical symp-
toms were manifested, and thereafter the diagnosis of metas-
tases was confirmed radiographically. In contrast, in the 27
patients remaining disease free, the 90K level before surgery
was relatively low (6.9 ± 3.8 U ml-') and remained within the
normal range after surgery, with the exception of five
patients who showed an increase above the cut-off during the
investigation period.
Table II Relationship between 90K serum levels and clinicopatho-
logical features in patients with breast cancer apparently free ofdisease
after surgery
90Kpositivea 90K negative
Variable no. (%) no. (%) P-value
Age (years)
<50 29 (16) 156 (84) NS
>50 40 (17) 200 (83)
Menopausal status
Premenopausal 36 (17) 180 (83) NS
Post-menopausal 41 (20) 168 (80)
Lymph node status
Negative 32 (14) 188 (86) NS
Positive 35 (17) 170 (83)
ER status
Negative 82 (42) 113 (58) NS
Positive 99 (43) 131 (57)
Tumour size (cm)
K,2 13(16) 70(84) 006
>2 89 (26) 253 (74)
Histological category
Ductal 71 (19) 295 (81) NS
Non-ductal 6 (10) 53 (90)
aPatients with serum 90K levels >11 Uml-' were labelled as 90K
positive. NS, not significant.174 S. IACOBELLI et al.
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Circulating 90K levels were positive in 159 of 310 (51.3%) 286) patients with metastatic breast cancer (Table I). The mean
level was 17.8 ± 9.3 Uml-4, which was 3.2 times higher than
in controls. The 90K-positive rate did not correlate with size,
histology and oestrogen receptor status of the primary
89) tumour (Table IV). High 90K levels were significantly cor-
related with metastatic liver involvement (P = 0.009), a
disease-free interval of less than 12 months (P = 0.005) and
an age of less than 50 years (P = 0.01). Also, there was a
trend for patients with more than one metastatic site to have
036 more frequently increased 90K serum levels (P= 0.07, Table IV).
b Discussion
In the present study, we monitored the levels of circulating No. = 152) serum 90K antigen in patients with breast cancer. We further
investigated whether serum 90K plays a role in the biological
behaviour of this malignancy.
First we examined the clinical usefulness of 90K in the
~(No- = 46) post-surgical follow-up of NED patients. The results showed
-.. that those patients with node-positive disease and 90K serum
levels higher than the cut-off value (11 U ml-') had a shorter
overall survival than patients with lower 90K levels, indepen-
dent of other prognostic factors. In node-negative patients,
P= 0.004 90K failed to predict clinical outcome. The reason for this is
currently unclear. We also obtained evidence that 90K is able
to detect early relapse during post-surgical follow-up. Indeed,
c of patients that developed metastatic disease, nearly all
= 43) showed increasing 90K serum levels over time, while in the
majority of patients without relapse 90K remained at low
134) levels. In a few patients, metastatic disease was predicted by
0.50 -
0.25
0-
30 T
25 .
P = 0.62
0 10 20 30 40 50 60 70 80
Months
Figure 1 Overall survival of patients as a function of axillary
lymph node status: 90K positive (>11 U ml-, ----) and 90K
negative (< 11 U ml- , ). a, Whole patient population; b,
node positive; c, node negative.
Table III Proportional hazards general linear model of survival in
patients with node-positive breast cancer
Relative risk of
Variable pa death P-value
No. of positive nodes 1.17 3.22
(1-3 vs >3) (1.56-6.64)b 0.001
Tumour size 0.65 1.91
(< 2 cm vs >2cm) (0.95-3.84) 0.085
90K 0.87 2.4
(,<IUml-'vs (1.27-4.49) 0.005
>11 Uml-,)
Age (years) - NS
( < 50 vs >50)
ER status NS
(negative vs positive)
aEstimated regression coefficient of the hazard function. b95%
confidence limits are given for the relative risk of death. NS, not
significant.
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Figure 2 Serum 90K levels in patients with breast cancer
remaining free of disease or developing metastases. In the
patients indicated by arrows, the re-elevation of 90K level was
observed before the clinical symptoms were manifested and diag-
nosis of metastatic disease was confirmed.
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Table IV Elevated 90K levels in patients with metastatic breast
cancer
90Kpositivea 90K negative
no. (%) no. (%) P-value
Age (years)
<50 85 (60) 57 (40) 0.01
>50 76 (45) 92 (55)
No of metastases
Single 34 (65) 18 (35) 0.07
Multiple 130 (50) 128 (50)
Liver involvement
No 38 (27) 100 (73) 0.009
Yes 73 (42) 99 (58)
Size of the primary tumour
<2cm 49 (51) 46 (49) NS
>2 cm 95 (44) 120 (56)
Histology
Ductal 126 (55) 114 (45) NS
Non-ductal 44 (63) 26 (37)
ER status of the primary tumour
Positive 96 (51) 92 (49) NS
Negative 63 (52) 59 (48)
Disease-free interval
< 12 months 30 (79) 8 (21) 0.01
>12 months 134 (55) 108 (45)
aPatients with serum 90K levels >11 Uml-' were labelled as 90K
positive. NS, not significant.
an elevation of 90K before confirmation of diagnosis by
radiographic examination. This suggests that 90K is a strong
indicator of tumour relapse. This would make it possible to
select subgroups of patients most suited to receive more
aggressive adjuvant treatment and/or a closer post-operative
follow-up and suggests the importance of serial determina-
tions of serum 90K for early detection of metastases. In this
respect, it should be emphasised that the new 90K IRMA
described in this article has proven to be easier to perform
and more rapid and accurate than the previous ELISA.
Determination of 90K in 425 breast cancer NED patients
revealed supranormal 90K serum levels in 18.5% of cases.
This figure is higher than the percentages of elevated values
observed with CA 15-3 or CEA in the same category of
patients (Ingersleben et al., 1987; Colomer et al., 1989). High
90K levels in patients apparently free of disease could be
considered as a sign of occult cancer. Although this point
was not specifically addressed in our study, it is interesting to
report that an elevation of 90K serum levels after adminis-
tration of recombinant interferon a was associated with early
relapse in NED cancer patients (Scambia et al., 1991; Natoli
et al., 1993).
Regarding advanced breast cancer, 90K seems to be re-
lated to a more severe course of the disease. Though only
about one-half of patients with metastatic disease had sup-
ranormal 90K serum levels, a correlation was found with
metastatic liver involvement, a shorter disease-free interval
and a younger age. On the contrary, there was no clear
correlation with number of metastatic sites. This suggests
that circulating 90K levels may be influenced by other fac-
tors, such as the biological characteristics of the tumour itself
and the ability of cancer cells to produce and secrete the
antigen into the circulation. In this regard, we do not know
whether the amount of 90K in serum reflects changes in
synthesis or secretion of 90K from cancer cells. We are
currently investigating the relationship between the expres-
sion of this antigen in cancer tissues by immunohistochemical
staining and circulating serum levels. To date, we have been
unable to demonstrate any correlation (unpublished data).
Finally, although the original MAb SP-2 recognising 90K
was raised against proteins released from breast cancer cells
(Iacobelli et al., 1986), we cannot exclude the possibility that
a proportion of serum 90K may derive from other sources,
such as liver, either directly or as a consequence of the
metastatic involvement.
We have previously shown that 90K antigen is not related
to other circulating breast cancer markers such as CA 15-3
and CEA (lacobelli et al., 1988). Other tumour-associated
antigens shown to be expressed by breast cancers with appar-
ent molecular weight of approximately 90,000 daltons are
likely to represent distinct molecules for the following
reasons. The antigen recognised by MAb B6.2 (Kufe et al.,
1983; Schlom et al., 1984) is a surface glycoprotein and
therefore distinct from 90K, which is localised in the cyto-
plasm (lacobelli et al., 1988). Moreover, in contrast to 90K,
the MAb B.2-defined antigen is restricted to breast cancer
cells. The antigen recognised by MAb 465.12S (Natali et al.,
1982) is also a cell-surface glycoprotein and therefore distinct
from 90K (Iacobelli et al., 1986). The melanoma-associated
antigen termed p97, gp87 or gp95 (Dippold et al., 1980;
Brown et al., 1981; Liao et al., 1985) is a membrane protein
that is structurally related to transferrin (Brown et al., 1982).
Another melanoma antigen, FD, is also a cell-surface glyco-
protein whose expression is restricted to a very limited
number of cells (Mattes et al., 1987). Further, the antigen
defined by MAb 3G2-C6 (Zhang & Lin, 1989) is a cell-
surface component expressed in a significant number of blad-
der cancers but rarely present in breast cancers (Young et al.,
1985).
Finally, that 90K is distinct from other tumour markers is
confirmed by our recent data showing that the protein has an
amino-terminal sequence not previously described (lacobelli
et al., 1993).
In summary, we feel that the assay of 90K in serum may
have clinical potential not only as a cancer monitoring test,
but also as a prognostic factor.
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